Global /Denmark /Healthcare /Biotechnology /BAVA
chevron_leftBack

Bavarian Nordic A/S

BAVA
CPH: BAVA Delayed
151.85DKK -0.9%
23.15 USD
As of 24 April 2025, Bavarian Nordic A/S has a market cap of $1.82B USD, ranking #5699 globally and #33 in Denmark. It ranks #519 in the Healthcare sector, and #129 in the Biotechnology industry.
Global Rank
5699
Country Rank
33
Sector Rank
519
Industry Rank
129
Key Stats
Market Cap
$1.82BUSD
11.92B DKK
Enterprise Value
$1.51BUSD
9.91B DKK
Revenue (TTM)
$871.32MUSD
5.72B DKK
EBITDA (TTM)
$248.22MUSD
1.63B DKK
Net Income (TTM)
$150.6MUSD
987.98M DKK
EBITDA Margin
28%
Profit Margin
17%
PE Ratio
12.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Paul Chaplin open_in_new
Employees
1,605
Founded
1992
Website
bavarian-nordic.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-0.9% 4.4% -7.1% -23% -33% 0.3%
Upcoming Earnings
Earnings Date
Fri, May 9

Markets

Exchange Ticker Price
Nasdaq Copenhagen
MIC: XCSE
PRIMARY
BAVA
Bavarian Nordic AS
ISIN: DK0015998017
Shares Out.:
78.549M1 Shares Float: 77.508M2
TV:
SA:
YF:
GF:
BA:
MS:
151.85 DKK
London Stock Exchange
MIC: XLON
0DPB
Bavarian Nordic AS
ISIN: DK0015998017
TV:
SA:
YF:
GF:
BA:
MS:
153.25 DKK
OTC Markets
MIC: OTCM
BVNKF
Bavarian Nordic AS
ISIN: DK0015998017
TV:
SA:
YF:
GF:
BA:
MS:
21.74 USD
OTC Markets
MIC: OTCM
BVNRY
Bavarian Nordic AS ADR
ISIN: US0717711099
TV:
SA:
YF:
GF:
BA:
MS:
7.36 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Similar Companies

Industry: Biotechnology (Denmark)
Name
Market Cap diff.
Genmab A/S
GMAB
$12.69B
83.24B DKK
598%
Ascendis Pharma A/S
ASND
$9.51B
423%
ALK-Abelló A/S
ALK-B
$4.98B
32.65B DKK
174%
Zealand Pharma A/S
ZEAL
$4.37B
28.7B DKK
141%
Gubra A/S
GUBRA
$897.82M
5.89B DKK
-51%
Industry: Biotechnology (Global)
Name
Market Cap diff.
Vertex Pharmaceuticals Inc.
VRTX
$126.59B
7K%
CSL Ltd.
CSL
$74.13B
116.09B AUD
4K%
Regeneron Pharmaceuticals, Inc.
REGN
$62.91B
3K%
Samsung Biologics Co.,Ltd.
207940
$52.85B
75.87T KRW
3K%
argenx SE
ARGX
$36.66B
32.22B EUR
2K%